Pelthos Therapeutics Inc.
PTHS- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001919246
In the last 90 days, Pelthos Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $37.4M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Pelthos Therapeutics Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Q3 2024 | Change |
|---|---|---|---|
| Holders | 5 | 5 | 0 |
| Shares | 219.9K | 83.9K | −136.0K (−61.8%) |
| Value | $290.3K | $59.6K | −$230.7K (−79.5%) |
New holders (3)
Institutions that held Pelthos Therapeutics Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Avantax Planning Partners, Inc. | 47,205 | $33.5K | 0.00% |
| Two Sigma Securities, LLC | 26,061 | $18.5K | 0.00% |
| Wealth Enhancement Advisory Services, LLC | 10,400 | $7.38K | 0.00% |
Sold out (3)
Institutions that held Pelthos Therapeutics Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Anson Funds Management LP | 201,030 | $265.4K |
| Citadel Advisors LLC | 18,714 | $24.7K |
| UBS Group AG | 186 | $246 |